Abstract
Despite evidence that smoking confers protection against neurological disorders, how and whether specific nicotinic receptor subtypes are involved is unknown. We reported previously that nicotine suppresses constitutive nuclear factor κB (NF-κB) activity and thereby proinflammatory cytokine (PIC) production in SHEP1 cells stably transfected with α4β2 nicotinic receptors. Here, we report the anti-inflammatory effects of nicotine pretreatment in lipopolysaccharide (LPS)-stimulated SHEP1 cells. Nicotine (100–300 nM, concentrations found in smoker's blood) blocked LPS-induced NF-κB translocation and production of PICs interleukin (IL)-1β and IL-6 but only partially blocked inhibitor of nuclear factor-κBα (IκBα) phosphorylation. These effects were exclusively in cells transfected with α4β2 receptors but not in wild types. The cell-permeable calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid-acetoxymethyl ester, the adenylate cyclase stimulant forskolin, and a specific protein kinase A (PKA) inhibitor PKI 14-22-amide failed to block the effect of nicotine on LPS-induced NF-κB translocation and IκBα phosphorylation. However, the effects of nicotine on NF-κB activity were significantly blocked by the highly specific janus kinase 2 (JAK2) inhibitor α-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG-490) and the signal transducer and activator of transcription 3 (STAT3) inhibitor 2-hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid (NSC74859). These findings reveal a calcium- and cAMP-PKA-independent signaling cascade and suggest a role for JAK2-STAT3 transduction in α4β2-mediated attenuation of LPS-induced inflammation. Anti-inflammatory effects of nicotine may therefore be mediated through α4β2 receptors, the predominant high-affinity binding sites for nicotine in the central nervous system, in addition to the better-established α7 receptors.
Footnotes
This research was supported in part by Northeastern University (Research and Scholarship Development Fund Grant); and by private consulting unrelated to this project.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.066381.
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- AD
- Alzheimer's disease
- BAPTA
- 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
- AM
- acetoxymethyl ester
- hα4β2 SHEP1
- human SHEP1 neuroblastoma-derived cells stably transfected with human α4β2 nicotinic receptors
- HBSS
- Hanks' balanced salt solution
- IκBα
- inhibitor of nuclear factor of κ light polypeptide gene enhancer in B-cells, α
- JAK2
- Janus kinase 2
- nAChR
- nicotinic acetylcholine receptor
- NF-κB
- nuclear factor κB
- PBS
- phosphate-buffered saline
- PD
- Parkinson's disease
- PIC
- proinflammatory cytokine
- RFU
- relative fluorescence units
- STAT3
- signal transducer and activator of transcription 3
- TLR4
- Toll-like receptor 4
- AG-490
- α-cyano-(3,4-dihydroxy)-N-benzylcinnamide
- NSC74859
- 2-hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid
- CNS
- central nervous system
- PKA
- protein kinase A
- IL
- interleukin
- LPS
- lipopolysaccharide
- RT
- room temperature
- TBS
- Tris-buffered saline
- HRP
- horseradish peroxidase
- TNFα
- tumor necrosis factor α
- ELISA
- enzyme-linked immunosorbent assay
- A23187
- calcimycin.
- Received May 17, 2010.
- Accepted October 13, 2010.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|